In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

[1]  M. Louie,et al.  Synergy Testing of Vancomycin-Resistant Enterococcus faecium against Quinupristin-Dalfopristin in Combination with Other Antimicrobial Agents , 1999, Antimicrobial Agents and Chemotherapy.

[2]  T. Ng,et al.  Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong , 1999, Antimicrobial Agents and Chemotherapy.

[3]  N. Jacobus,et al.  In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936) , 1999, Antimicrobial Agents and Chemotherapy.

[4]  A. Simor,et al.  Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J J Schentag,et al.  Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. , 1998, Diagnostic microbiology and infectious disease.

[6]  G. Kaatz,et al.  Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium , 1998, Antimicrobial Agents and Chemotherapy.

[7]  Robin Patel,et al.  Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci , 1997, Journal of clinical microbiology.

[8]  J. Jorgensen,et al.  In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species , 1997, Antimicrobial agents and chemotherapy.

[9]  V. Yu,et al.  In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis , 1996, Antimicrobial agents and chemotherapy.

[10]  A. C. McIntosh,et al.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci , 1996, Antimicrobial agents and chemotherapy.

[11]  G. Eliopoulos,et al.  In vitro activities in new oxazolidinone antimicrobial agents against enterococci , 1996, Antimicrobial agents and chemotherapy.

[12]  T. F. Butler,et al.  Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. , 1996, The Journal of antibiotics.

[13]  D. Wilson,et al.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections , 1996, Antimicrobial agents and chemotherapy.

[14]  J. Kilburn,et al.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents , 1996, Antimicrobial agents and chemotherapy.

[15]  S. Kaplan,et al.  In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae , 1996, Antimicrobial agents and chemotherapy.

[16]  M. Jacobs,et al.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci , 1996, Antimicrobial agents and chemotherapy.

[17]  T. Nicas,et al.  Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria , 1995, Antimicrobial agents and chemotherapy.

[18]  S. Handwerger,et al.  Inducible and constitutive expression of vanC-1-encoded resistance to vancomycin in Enterococcus gallinarum , 1995, Antimicrobial agents and chemotherapy.

[19]  G. Trenholme,et al.  In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. , 1993, The Journal of infectious diseases.

[20]  W. Noble,et al.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. , 1992, FEMS microbiology letters.

[21]  S Chattopadhyay,et al.  Production of L-dopa by Aspergillus terreus. , 1990, FEMS microbiology letters.

[22]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[23]  M. Zervos,et al.  Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.